Arbutus reports fourth quarter and year end 2023 financial results and provides corporate update

On-track to report key clinical data in 2024 from two on-going phase 2a clinical trials with imdusiran and the phase 1a/1b clinical trial with ab-101

ABUS Ratings Summary

ABUS Quant Ranking